Headache

Papers
(The H4-Index of Headache is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Pilot study evaluating treatment with sumatriptan for moderate to severe post‐traumatic headache: A phase 2 open‐label study169
Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers86
Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions63
Virtual issue: Education in headache medicine: Insights and advancements from 2023 to 202463
Evidence for increased background neural noise in migraine with aura: Hyperactive but not hyperresponsive61
Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study51
A retrospective analysis of the use of candesartan for migraine prevention in adolescents46
Erratum44
Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clin43
Facial variant of epicrania fugax secondary to a cerebellopontine angle meningioma43
Drug‐resistant epicrania fugax: Responding to onabotulinumtoxinA39
Temporary occipital nerve stimulation as transitional therapy for chronic intractable cluster headache: A case report and proof of concept39
Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked38
Cortical synchronization of spontaneous trigeminal neuropathic pain monitored with in vivo optical imaging of calcium activity in freely moving mice36
Anxiety, depression, and headache‐related disability in a large pediatric clinic–based sample35
Migraine screening in English and Spanish34
Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment34
Migraine and peripheral pain models show differential alterations in neuronal complexity34
Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine31
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine28
A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine28
Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society28
Normal glymphatic system function in patients with new daily persistent headache using diffusion tensor image analysis along the perivascular space28
Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study27
A retrospective review of sex differences of white matter hyperintensities in brain MRI of patients with migraine27
Patient headache questionnaires can improve headache diagnosis and treatment in children26
Sequential administration of peripheral nerve blocks and  onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A ret26
Sex and gender: Opportunities to expand research and understanding within headache medicine26
Index26
Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐bl26
Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Associa26
0.18939089775085